Cargando…

Empirical and Rational Design of T Cell Receptor-Based Immunotherapies

The use of T cells reactive with intracellular tumor-associated or tumor-specific antigens has been a promising strategy for cancer immunotherapies in the past three decades, but the approach has been constrained by a limited understanding of the T cell receptor’s (TCR) complex functions and specifi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jones, Heather F., Molvi, Zaki, Klatt, Martin G., Dao, Tao, Scheinberg, David A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7868419/ https://www.ncbi.nlm.nih.gov/pubmed/33569049 http://dx.doi.org/10.3389/fimmu.2020.585385

Ejemplares similares

The landscape of MHC-presented phosphopeptides yields actionable shared tumor antigens for cancer immunotherapy across multiple HLA alleles
por: Molvi, Zaki, et al.
Publicado: (2023)

The landscape of MHC-presented phosphopeptides yields actionable shared tumor antigens for cancer immunotherapy across multiple HLA alleles
por: Molvi, Zaki, et al.
Publicado: (2023)

Structure-Based, Rational Design of T Cell Receptors
por: Zoete, V., et al.
Publicado: (2013)

Unmasking the suppressed immunopeptidome of EZH2-mutated diffuse large B-cell lymphomas through combination drug treatment
por: Bourne, Christopher M., et al.
Publicado: (2022)

A TCR mimic monoclonal antibody reactive with the “public” phospho-neoantigen pIRS2/HLA-A*02:01 complex
por: Dao, Tao, et al.
Publicado: (2022)

Elucidating the direct effects of the novel HDAC inhibitor bocodepsin (OKI-179) on T cells to rationally design regimens for combining with immunotherapy
por: Holay, Nisha, et al.
Publicado: (2023)

Vaccines: From Empirical Development to Rational Design
por: Rueckert, Christine, et al.
Publicado: (2012)

Low-dose CDK4/6 inhibitors induce presentation of pathway specific MHC ligands as potential targets for cancer immunotherapy
por: Charles, Angel, et al.
Publicado: (2021)

Therapeutic immunomodulation by rationally designed nucleic acids and nucleic acid nanoparticles
por: Panigaj, Martin, et al.
Publicado: (2023)

Multidimensional Analyses of Tumor Immune Microenvironment Reveal the Possible Rationality of Immunotherapy and Identify High Immunotherapy Response Subtypes for Renal Papillary Cell Carcinoma
por: Wei, Baojun, et al.
Publicado: (2021)

Moving from Empirical to Rational Vaccine Design in the ‘Omics’ Era
por: Sharma, Mansi, et al.
Publicado: (2019)

Mapping Determinants of Virus Neutralization and Viral Escape for Rational Design of a Hepatitis C Virus Vaccine
por: Keck, Mei-Le, et al.
Publicado: (2018)

The Mechanism of Action of Antigen Processing Independent T Cell Epitopes Designed for Immunotherapy of Autoimmune Diseases
por: Shepard, Ella R., et al.
Publicado: (2021)

Vaccine Adjuvant Informatics: From Data Integration and Analysis to Rational Vaccine Adjuvant Design
por: He, Yongqun
Publicado: (2014)

Mechanisms of Immune Control of Mucosal HSV Infection: A Guide to Rational Vaccine Design
por: Truong, Naomi R., et al.
Publicado: (2019)

Cytomegalovirus-specific T cells following haploidentical transplants: reshaping a repertoire by half
por: O’Reilly, Richard J., et al.
Publicado: (2022)

Immunopeptidomics-Guided Warehouse Design for Peptide-Based Immunotherapy in Chronic Lymphocytic Leukemia
por: Nelde, Annika, et al.
Publicado: (2021)

Glycoconjugate Nanoparticle-Based Systems in Cancer Immunotherapy: Novel Designs and Recent Updates
por: Barchi, Joseph J.
Publicado: (2022)

Reprogramming viral immune evasion for a rational design of next-generation vaccines for RNA viruses
por: Su, Chia-Ming, et al.
Publicado: (2023)

Rational Vaccinology: Harnessing Nanoscale Chemical Design for Cancer Immunotherapy
por: Huang, Ziyin, et al.
Publicado: (2022)

Rational Design of Gene Therapy Vectors
por: Pan, Dao, et al.
Publicado: (2019)

Identification of New Features from Known Bacterial Protective Vaccine Antigens Enhances Rational Vaccine Design
por: Ong, Edison, et al.
Publicado: (2017)

Rational Design of a Chimeric Derivative of PcrV as a Subunit Vaccine Against Pseudomonas aeruginosa
por: Wan, Chuang, et al.
Publicado: (2019)

Rational Design of Antigen Incorporation Into Subunit Vaccine Biomaterials Can Enhance Antigen-Specific Immune Responses
por: Tsoras, Alexandra N., et al.
Publicado: (2020)

Mesenchymal Stromal Cells Based Therapy in Systemic Sclerosis: Rational and Challenges
por: Peltzer, Juliette, et al.
Publicado: (2018)

Bibliometric Analysis of Chimeric Antigen Receptor-Based Immunotherapy in Cancers From 2001 to 2021
por: Ou, Zhanpeng, et al.
Publicado: (2022)

Editorial: Cytokine and cytokine receptor-based immunotherapies: Updates, controversies, challenges, and future perspectives
por: Wang, Jun, et al.
Publicado: (2022)

Development of a Preventive HIV Vaccine Requires Solving Inverse Problems Which Is Unattainable by Rational Vaccine Design
por: Van Regenmortel, Marc H. V.
Publicado: (2018)

Understanding the role of Toll-like receptors in lung cancer immunity and immunotherapy
por: Hoden, Bettina, et al.
Publicado: (2022)

Toll-Like Receptor-4 Modulation for Cancer Immunotherapy
por: Awasthi, Shanjana
Publicado: (2014)

Toll-like Receptors in Ovarian Cancer as Targets for Immunotherapies
por: Muccioli, Maria, et al.
Publicado: (2014)

Chemokines and Chemokine Receptors: New Targets for Cancer Immunotherapy
por: Mollica Poeta, Valeria, et al.
Publicado: (2019)

Toll-Like Receptor Agonists as Adjuvants for Allergen Immunotherapy
por: Kirtland, Max E., et al.
Publicado: (2020)

Rational design of universal immunotherapy for TfR1-tropic arenaviruses
por: Cohen-Dvashi, Hadas, et al.
Publicado: (2020)

Nosocomial Pneumonia: Rationalizing the Approach to Empirical Therapy
por: Andriesse, Gunnar I., et al.
Publicado: (2012)

The Immunogenicity and Anti-tumor Efficacy of a Rationally Designed Neoantigen Vaccine for B16F10 Mouse Melanoma
por: Zhang, Yan, et al.
Publicado: (2019)

Empirical causality analysis in strategic planning
por: Klatt, Tobias
Publicado: (2011)

Dendritic Cell-Based Immunotherapy for Myeloid Leukemias
por: Schürch, Christian M., et al.
Publicado: (2013)

Chemokine Receptor-Specific Antibodies in Cancer Immunotherapy: Achievements and Challenges
por: Vela, Maria, et al.
Publicado: (2015)

Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors
por: Kosti, Paris, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ge9cbsnl90urdnkm00j1s0r2dp